Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
inno-ME
Beijing, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead program YN001, a targeted therapy for atherosclerosis using a unique active targeting nanoparticle delivery, has received IND approval from US FDA and China NMPA and entered clinical trials. This is the first cardiovascular targeted drug of its kind to do so and could be the first to gain FDA Accelerated Approval for this indication.
- Therapeutic areas
- OncologyImmunologyCardiovascular
- Modalities
- NanoparticleLiposome-based drug deliverySmall molecule
- Industry
- Biotech
02
Partnerships
Beijing Anzhen Hospital (for technology transfer and development)
Beyond the preview
Go deeper on inno-ME.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inno-ME.